Products for Research Use Only

Lanreotide (diTFA)

CAT: 0804-HY-P1959BSize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P1959BSize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Lanreotide (BIM 23014) diTFA is a somatostatin analogue with antineoplastic activity. Lanreotide diTFA can be used for the research of carcinoid syndrome[1][2].
CAS Number
1024499-83-9
Product Name Alternative
BIM 23014 (diTFA)
UNSPSC
12352209
Target
Somatostatin Receptor
Type
Peptides
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cancer; Endocrinology
Assay Protocol
https://www.medchemexpress.com/lanreotide-ditfa.html
Solubility
10 mM in DMSO
Smiles
O=C([C@@H](NC([C@@](CSSC[C@@H](C(N[C@H](C(N)=O)[C@H](O)C)=O)NC([C@H](C(C)C)NC([C@@](CCCCN)([H])NC1=O)=O)=O)([H])NC([C@H](N)CC2=CC3=CC=CC=C3C=C2)=O)=O)CC4=CC=C(O)C=C4)N[C@@H]1CC5=CNC6=C5C=CC=C6.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O
Molecular Formula
C58H71F6N11O14S2
Molecular Weight
1324.37
References & Citations
[1]Ning S, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Endocr Relat Cancer. 2009 Sep;16 (3) :1045-55.|[2]Florio T, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Clin Endocrinol (Oxf) . 2003 Jul;59 (1) :115-28.
Shipping Conditions
Room temperature
Scientific Category
Peptides
Clinical Information
Launched

Popular Products